7+3 (Chemotherapy)

The 7+3 regimen is a chemotherapy regimen used as first line induction therapy to bring about remission in acute myeloid leukemia, excluding the acute promyelocytic form of the disease, which is treated differently. It combines seven days of continuous intravenous cytarabine with three concurrent days of an anthracycline, most often daunorubicin, though idarubicin, doxorubicin, or mitoxantrone can be substituted. Developed in 1973, the combination has remained the backbone of standard induction therapy for acute myeloid leukemia for close to five decades, with roughly 35 to 40 percent of younger adult patients becoming long term survivors after starting treatment with it.